International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Artificial Neural Networks in Early Diagnosis of Neurological Disorders: A Review of Models, Biomarkers, and Clinical Integration

G.Hemalatha[1], K. Kaviya[2], Dr. S. Swarnalatha[3]

[1] B. pharm, M. Pharm*,
[3] Mpharm, Ph.D,
[2] B. pharm, M. Pharm.
Institution Name: Pallavan Pharmacy College

ABSTRACT :

Neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy, present significant diagnostic challenges due to their complex and progressive nature. Early detection is crucial for effective intervention, yet traditional diagnostic methods often rely on late-stage clinical symptoms. Artificial Neural Networks (ANNs) have emerged as powerful tools for analyzing multimodal biomarkers, including neuroimaging, genetic, and electrophysiological data, enabling earlier and more accurate diagnosis. This review explores the application of ANNs in the early diagnosis of neurological diseases, focusing on commonly used models, relevant biomarkers, and clinical integration strategies. To examine the advantages, current challenges, and future potential of ANN-based diagnostic tools in neurology. Additionally, to explore the limitations of current approaches, including data heterogeneity, interpretability issues, and ethical considerations.

Keywords: Neurological disorders, Artificial Neural Networks (ANNs), multimodal biomarkers, neuroimaging, genetic, and electrophysiological data.

Introduction

Neurological disorders like Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis impact millions of people around the world, causing significant physical, cognitive, and emotional challenges. For the purpose of implementing early interventions that can help slow down the progression of the disease, timely diagnosis is essential.Conventional diagnostic approaches often depend on clinical assessments and imaging techniques, which may overlook subtle initial indicators.

The incorporation of artificial intelligence (AI), particularly artificial neural networks (ANNs), into the diagnostic process presents a promising alternative. ANNs are capable of analyzing and interpreting complex, high-dimensional data sets, such as imaging, genetic, and clinical information, making them well-suited for identifying early pathological changes. This review seeks to provide an overview of ANN applications in neurological diagnostics, the biomarkers involved, and their integration into clinical practice.

Overview of Artificial Neural Networks

The structure of the human brain serves as the inspiration for artificial neural networks, which are computer systems.They consist of interconnected nodes (neurons) organized in layers, and ANNs learn to recognize patterns within data by training on labeled datasets. While ANNs are proficient at identifying patterns, they necessitate substantial datasets and effective training to prevent overfitting and enhance generalization.

Key ANN Architectures:

Multilayer Perceptrons (MLPs): Ideal for classifying structured data.
Convolutional Neural Networks (CNNs): Commonly utilized in image diagnostics, especially neuroimaging.
Recurrent Neural Networks (RNNs): Efficient for the analysis of time-series data such as EEG.
Deep Neural Networks (DNNs): Contain numerous hidden layers to perform complex feature extraction.

Feedforward Neural Networks (FNNs)

These are employed for analyzing static data (such as genetic risk scores and cerebrospinal fluid biomarkers). They are used to predict Alzheimer's disease by measuring tau and amyloid-beta protein levels.

2.2 Convolutional Neural Networks (CNNs)

These networks are predominant in the analysis of neuroimaging (MRI, fMRI, PET scans). They identify structural and functional irregularities in the early stages of neurodegeneration. Utilizing transfer learning with pre-trained models (like ResNet and VGG) enhances performance on smaller datasets.

2.3 Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) Networks

These networks are utilized for analyzing temporal data (including EEG, MEG, and gait patterns related to Parkinson’s disease). They help detect seizure onset in epilepsy through processing EEG signals.

2.4 Hybrid and Attention-Based Models

These models merge CNNs and LSTMs for the fusion of multimodal data. Transformer-based models (such as Vision Transformers) exhibit potential in neuroimaging applications

Biomarkers in Neurological Disorders

Biomarkers are often used to diagnose neurological illnesses because they are measurable signs of biological activity. Artificial Neural Networks (ANNs) utilize these markers to detect signs of disease in its early stages.

3.1 Biochemical Biomarkers:

Cerebrospinal fluid proteins: Levels of Tau and beta-amyloid in Alzheimer’s disease. Inflammatory indicators: Cytokine levels in multiple sclerosis.

3.2 Neuroimaging Biomarkers Structural MRI:

Thinning of the cortex and atrophy of the hippocampus (in Alzheimer’s). Functional MRI (fMRI): Changes in connectivity networks. PET Scans: Deposits of amyloid and tau proteins.

3.3 Electrophysiological Biomarkers EEG:

EEG: Creutzfeldt-Jakob disease and epilepsy are characterized by irregular wave patterns.

3.4 Genetic and Molecular Biomarkers

APOE-ε4 gene variant associated with Alzheimer’s, mutations in SNCA linked to Parkinson’s disease. Integration of liquid biopsy and omics data.

3.4 Digital and Behavioral Biomarkers

Utilization of speech analysis, gait monitoring, and eye-tracking technologies for the early detection of Parkinson’s disease.

ANN Models in Early Diagnosis

4.1 Alzheimer's Disease:

CNNs that are trained on MRI and PET scans have demonstrated high accuracy (over 90%) in identifying early-stage Alzheimer’s. Deep learning models also integrate CSF biomarkers and genetic information.

4.2 Parkinson’s Disease:

RNNs that analyze gait patterns, speech characteristics, and dopamine transporter imaging (DAT-SPECT) have exhibited promise for early detection.

4.3 Epilepsy:

ANNs trained on EEG data can effectively classify different seizure types and forecast seizure occurrences with high temporal precision.

4.4 Multiple Sclerosis:

ANNs utilizing MRI data can identify lesion progression and distinguish between different subtypes of MS.

5. Summary of Performance

Disorder	Model Type	Data Used	Accuracy
Alzheimer’s	CNN	MRI, PET, CSF, Genetics	90–96%
Parkinson’s	RNN, DNN	Speech, Imaging, Gait	85–92%
Epilepsy	RNN, CNN	EEG	88–95%
Multiple Sclerosis	CNN, MLP	MRI	82–90%

6. Clinical Data Integration and Real-World Application

For ANN models to be effective in a clinical setting, they need to incorporate a wide range of patient information, such as:

- Electronic Health Records (EHRs)
- Family medical history and patient demographics
- Clinical evaluations (for example, MMSE scores)

Instances of real-world applications include:

- IBM Watson Health employs AI to aid in diagnosing neurological conditions.
- DeepMind's AI has demonstrated promise in the interpretation of neuroimaging.

Clinical Integration Challenges

7.1 Data Limitations

- Limited and imbalanced datasets; insufficient representation of diverse populations.
- The requirement for cooperation between several centers and federated learning.

7.2 Interpretability and Trust

- The fact that deep learning models are opaque.
- Utilization of explainable AI (XAI) methods (such as SHAP and LIME) to gain clinician acceptance.

7.3 Regulatory and Ethical Concerns

- Approval from FDA/EMA for AI-driven diagnostic tools.
- Considerations around patient privacy, reduction of bias, and fairness in algorithms.

Challenges and Limitations

- Despite their promise, ANNs face several obstacles:
  Data Scarcity: High-quality, labeled neurological datasets are limited.
  Model Interpretability: The “black-box” nature of ANNs hinders clinical trust.
  Bias and Generalization: Models may perform poorly across diverse populations.
  Regulatory Barriers: Lack of standardized frameworks for clinical AI tools.

Future Directions

- The upcoming phase of research and development might encompass:
- Explainable AI (XAI): Enhancing transparency and fostering trust in the decisions made by artificial neural networks (ANN).
- Multimodal Integration: Merging imaging data, biomarkers, and electronic health records (EHRs).
- Federated Learning: Allowing data exchange between institutions while safeguarding privacy.
- Regulatory Guidelines: Creating clinical standards for the implementation of AI technologies.
- Personalized Medicine: Utilizing ANN to drive precision in neurology.
- Clinical Trials: Conducting prospective validations of ANN models in practical, real-world contexts.

Conclusion

Artificial neural networks offer a transformative approach to the early diagnosis of neurological disorders. By effectively analyzing biomarkers and integrating clinical data, ANNs have demonstrated high accuracy in various diagnostic tasks. Nonetheless, challenges in data access, model transparency, and clinical implementation must be addressed to fully realize their potential. Continued interdisciplinary collaboration is essential for the safe and effective integration of ANN-based tools into routine neurological care.

REFERENCES

1. Liu, Y. et al. (2022). "Deep Learning in Alzheimer's Diagnosis: A Review." *Frontiers in Aging Neuroscience*.
2. Chen, R. et al. (2021). "AI Applications in Parkinson's Disease." *Nature Reviews Neurology*.
3. Roy, Y. et al. (2019). "Deep Learning-Based Epileptic Seizure Detection." *IEEE Transactions on Neural Systems*.
4. Thompson, P.M. et al. (2020). "Imaging Biomarkers in MS." *The Lancet Neurology*.
5. *Esteva, A., et al. (2019).* "A guide to deep learning in healthcare." *Nature Medicine*, 25(1), 24–29.
6. *Jo, T., et al. (2019).* "Deep learning in Alzheimer’s disease: Diagnostic classification and prognostic prediction using neuroimaging data." *Frontiers in Aging Neuroscience*, 11, 220.
7. *Thomas, R. M., et al. (2020).* "Deep learning-based prediction of Alzheimer’s disease using neuroimaging: A systematic review." *IEEE Access*, 8, 111117–111132.
8. *Sarraf, S., and Tofighi, G. (2016).* "Deep learning-based pipeline to recognize Alzheimer’s disease using fMRI data." *arXiv preprint arXiv:1603.08631*.
9. *Vieira, S., et al. (2017).* "Using deep learning to investigate the neuroimaging correlates of psychiatric and neurological disorders: Methods and applications." *Neuroscience & Biobehavioral Reviews*, 74, 58–75.
10. *Ullah, I., et al. (2018).* "An automated system for epilepsy detection using EEG brain signals based on deep learning approach." *Expert Systems with Applications*, 107, 61–71.
11. *Shah, P., et al. (2019).* "Artificial intelligence and machine learning in clinical development: a translational perspective." *NPJ Digital Medicine*, 2(1), 69.
12. *Senders, J. T., et al. (2018).* "Machine learning and neurosurgical outcome prediction: a systematic review." *World Neurosurgery*, 109, 476–486.
13. *Lundervold, A. S., and Lundervold, A. (2019).* "An overview of deep learning in medical imaging focusing on MRI." *Zeitschrift für Medizinische Physik*, 29(2), 102–127.
14. *Litjens, G., et al. (2017).* "A survey on deep learning in medical image analysis." *Medical Image Analysis*, 42, 60–88.